Cipla growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+2.2%+6.9%+13.3%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
−17.5%+13.3%+25.1%
−22.4%+14.9%+35.9%
−26.7%+26.9%+46.6%
−26.4%+27.9%+47.0%
+13.7%+14.3%+11.0%
+10.3%+16.7%+13.0%
−21.3%+21.1%+27.7%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

CIPLA₹1,325.70

Cipla Ltd.

· Pharma & Health
₹ CrorePeersSUNPHARMADRREDDYLUPINAPOLLOHOSPMAXHEALTHDIVISLABTORNTPHARMZYDUSLIFEMcap ₹1.07L Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Revenue Growth—+13.3+6.9+2.2—
EBITDA Growth—+25.1+13.3-17.5—
EBIT Growth—+35.9+14.9-22.4—
Net Income Growth—+46.6+26.9-26.7—
EPS Growth—+47.0+27.9-26.4—
Total Assets Growth—+11.0+14.3+13.7—
Total Equity Growth—+13.0+16.7+10.3—
Cash from Operations Growth—+27.7+21.1-21.3—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 146%.